ASH News Daily 2017 - Issue 2 - A-1

Read this issue online at

www.hematology.org/ashnewsdaily2017_sunday
Follow us on Twitter using #ASH17

Schedule
11:15 a.m. - 12:15 p.m.
Continuing Conversations
with the Speakers
Georgia World Congress Center
(Building C, Level 1, C103)
11:15 a.m. - 12:15 p.m.
Featured Topic Discussion:
Hemophilia Revolution
Georgia World Congress Center
(Building B, Level 4, B405-B407)
11:15 a.m. - 12:15 p.m.
Quality Conversations on
Social Media: Achieving Credibility
and Efficiency Together
Georgia World Congress Center
(Building C, Level 2, C202-C204)
11:15 a.m. - 12:30 p.m.
ASH Practice Partnership Lunch
Omni Hotel at CNN Center
(International Ballroom, North Tower, M2)
12:30 - 1:30 p.m.
ASH/EHA Joint Symposium
Georgia World Congress Center
(Building C, Level 1, Hall C2-C3)
1:30 - 2:00 p.m.
Announcement of
Wallace H. Coulter Award
Georgia World Congress Center
(Building C, Level 1, Hall C2-C3)
2:00 - 4:00 p.m.
Plenary Scientific Session
4:30 - 6:00 p.m.
Blood and Beyond: The Art of Perception
Georgia World Congress Center
(Building A, Level 4, Marcus Auditorium)

Weather Update: As numerous session changes are in
effect, please refer to information provided at www.
hematology.org/atlanta prior
to planning your day.

New FDA Approvals for NHL and ALL:
Any Game Changers?
By Binod dhakal Md, MS, and
Mehdi haMadani, Md

n the past 15 years, tremendous
growth in scientific knowledge
has resulted in several blockbuster drugs that promise to improve the outlook of lymphoid
malignancies. This success story is
bolstered by the U.S. Food and Drug
Administration (FDA) approval of
several drugs to treat hematologic
malignancies. To discuss the new
approvals for non-Hodgkin lymphoma (NHL) and acute lymphocytic leukemia (ALL), this year's
ASH annual meeting will dedicate
a session at 4:00 p.m. today, chaired
by Dr. Richard Pazdur, director of
the FDA's Oncology Center of Excellence (OCE), in Hall C2-C3 of the
Georgia World Congress Center.
Because demonstrating improvement in overall survival (OS) is not
always practical and could delay
patient access to potentially effective therapies, the FDA relies on
two approval pathways, regular

and accelerated approval-both requiring substantial evidence from
well-designed studies. This year,
the FDA approved two gene therapies: Kymriah, a CAR T cell therapy

»» FDA Page A-2

Cardio-Hematology: The New Kid on the Block
By Farrukh awan, Md

esterday we bore witness to
the birth of a new field of
study during the "Special
Scientific Symposium on Hot Topics in Hematology: New Pathways
Linking Hematopoiesis, Thrombo-

sis, and Cardiovascular Disease,"
chaired by Dr. Cynthia E. Dunbar
of the National Heart, Lung, and
Blood Institute, National Institutes
of Health. Call it what you may, but
we are now moving into an era of
specialized discovery that is relevant across various medical disci-

IN THIS SECTION
Myeloma
A-7
DNA Sequencing
A-8
Visual Intelligence
A-9
Aggressive Lymphoma
A-12

for pediatric and adult patients with
ALL, and Yescarta, another CAR
T cell therapy for the treatment of

Dr. Benjamin Ebert presents "Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease" on Saturday.

plines. Discoveries in one field now
can now be used to further improve
the understanding of another, ultimately advancing the pace of innovation and affecting the outcomes
of our patients tremendously. Unfortunately, however, this session
was also a victim to the Atlanta
snow storm of 2017, and a couple of
the speakers were unable to make
it to the meeting. Nevertheless, we
proceeded with what turned out to
be a fascinating and enlightening
session, with Dr. Ebert presenting
and Dr. Weyrich filling in for Dr.
Abel.
Hematologic malignancies are
associated
with
gene-specific,
recurrent somatic mutations in
hematopoietic stem cells that increase in frequency with age, and
have been detected in more than
»» CARDIO-HEMATOLOGY Page A-3

http://www.hematology.org/ashnewsdaily2017_sunday http://www.hematology.org/atlanta http://www.hematology.org/atlanta

Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 2